Clinuvel Pharmaceuticals Extends CEO Philippe Wolgen's Term of Employment
MT Newswires Live
Jul 02
Clinuvel Pharmaceuticals (ASX:CUV) extended the term of employment for Chief Executive Philippe Wolgen through June 2029, according to a Thursday filing with the Australian bourse.
The executive's annual fixed base remuneration remains unchanged, while all retention payments have been discontinued, per the filing.
"For us it was obvious we needed to find a way to retain Philippe to execute a plan aiming to generate further value," said Clinuvel Chair Jeffrey Rosenfeld.
The company's shares fell nearly 1% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.